Drug news
NICE final guidance recommends Briique in Acute Coronary Syndrome
Brilique (ticagelor) from AstraZeneca has a positive recommendation from NICE, the health technology appraisal body for England and Wales in its final guidance. NICE recommends Brilique in combination with aspirin, for up to 12 months in patients with ST-segment-elevation myocardial infarction (STEMI) that is to be treated with primary percutaneous coronary intervention or non-ST-segment-elevation myocardial infarction (NSTEMI). It is also recommended for patients admitted to hospital with unstable angina.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.